{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:56:23Z","timestamp":1786982183908,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T00:00:00Z","timestamp":1649894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T00:00:00Z","timestamp":1649894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"DOI":"10.1007\/s12016-022-08938-w","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T06:03:30Z","timestamp":1649916210000},"page":"179-192","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Real-Life Effectiveness of Benralizumab, Mepolizumab and Omalizumab in Severe Allergic Asthma Associated with Nasal Polyps"],"prefix":"10.1007","volume":"64","author":[{"given":"Angelica","family":"Tiotiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Mendez-Brea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iulia","family":"Ioan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Romero-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Philippe","family":"Oster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi-cam-tu","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana Carolina","family":"Ochoa-Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Bonniaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"de Blay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco-Javier","family":"Gonzalez-Barcala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,14]]},"reference":[{"key":"8938_CR1","unstructured":"GINA Difficult-to-treat & severe asthma in adolescent and adult patients. Diagnosis and management; 2021. Available from: https:\/\/ginasthma.org\/wp-content\/uploads\/2021\/08\/SA-Pocket-guide-v3.0-SCREEN-WMS.pdf. [cited 2021 Nov 16]"},{"key":"8938_CR2","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/j.jaip.2019.02.030","volume":"7","author":"M Humbert","year":"2019","unstructured":"Humbert M, Bousquet J, Bachert C, Palomares O, Pfister P, Kottakis I et al (2019) IgE-mediated multimorbidities in allergic asthma and the potential for omalizumab therapy. J Allergy Clin Immunol Pract 7:1418\u20131429","journal-title":"J Allergy Clin Immunol Pract"},{"key":"8938_CR3","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1183\/13993003.00779-2015","volume":"46","author":"DE Shaw","year":"2015","unstructured":"Shaw DE, Sousa AR, Fowler SJ, Fleming LJ, Roberts G, Corfield J et al (2015) Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J 46:1308\u20131321","journal-title":"Eur Respir J"},{"key":"8938_CR4","doi-asserted-by":"publisher","unstructured":"Pretolani M, Soussan D, Poirier I, Thabut G, Aubier M, COBRA Study Group et al (2017) Clinical and biological characteristics of the French COBRA cohort of adult subjects with asthma. Eur Respir J\u00a050:1700019.\u00a0https:\/\/doi.org\/10.1183\/13993003.00019-2017","DOI":"10.1183\/13993003.00019-2017"},{"key":"8938_CR5","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.chest.2019.10.053","volume":"157","author":"E Wang","year":"2020","unstructured":"Wang E, Wechsler ME, Tran TN, Heaney LG, Jones RC, Menzies-Gow AN et al (2020) Characterization of severe asthma worldwide: data from the international severe asthma registry. Chest 157:790\u2013804","journal-title":"Chest"},{"key":"8938_CR6","doi-asserted-by":"crossref","unstructured":"Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S et al (2020) European position paper on rhinosinusitis and nasal polyps 2020. Rhinology\u00a058(Suppl S29):1\u2013464","DOI":"10.4193\/Rhin20.601"},{"key":"8938_CR7","doi-asserted-by":"publisher","first-page":"420","DOI":"10.4193\/Rhino09.095","volume":"48","author":"L Bilodeau","year":"2010","unstructured":"Bilodeau L, Boulay M-E, Prince P, Boisvert P, Boulet L-P (2010) Comparative clinical and airway inflammatory features of asthmatics with or without polyps. Rhinology 48:420\u2013425","journal-title":"Rhinology"},{"key":"8938_CR8","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1002\/lary.27852","volume":"129","author":"N Bhattacharyya","year":"2019","unstructured":"Bhattacharyya N, Villeneuve S, Joish VN, Amand C, Mannent L, Amin N et al (2019) Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps. Laryngoscope 129:1969\u20131975","journal-title":"Laryngoscope"},{"key":"8938_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2020.106080","volume":"171","author":"D Bagnasco","year":"2020","unstructured":"Bagnasco D, Brussino L, Bonavia M, Calzolari E, Caminati M, Caruso C et al (2020) Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis. Respir Med 171:106080. https:\/\/doi.org\/10.1016\/j.rmed.2020.106080","journal-title":"Respir Med"},{"key":"8938_CR10","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.jaip.2016.11.007","volume":"5","author":"JD Blakey","year":"2017","unstructured":"Blakey JD, Price DB, Pizzichini E, Popov TA, Dimitrov BD, Postma DS et al (2017) Identifying risk of future asthma attacks using UK medical record data: a respiratory effectiveness group initiative. J Allergy Clin Immunol Pract 5:1015\u20131024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"8938_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.12049","volume":"11","author":"C M\u00fcmmler","year":"2021","unstructured":"M\u00fcmmler C, D\u00fcnzelmann K, Kneidinger N, Barnikel M, Munker D, Gr\u00f6ger M et al (2021) Real-life effectiveness of biological therapies on symptoms in severe asthma with comorbid CRSwNP. Clin Transl Allergy 11:e12049. https:\/\/doi.org\/10.1002\/clt2.12049","journal-title":"Clin Transl Allergy"},{"key":"8938_CR12","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","volume":"394","author":"C Bachert","year":"2019","unstructured":"Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE et al (2019) Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 394:1638\u20131650","journal-title":"Lancet"},{"key":"8938_CR13","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","volume":"146","author":"P Gevaert","year":"2020","unstructured":"Gevaert P, Omachi TA, Corren J, Mullol J, Han J, Lee SE et al (2020) Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol 146:595\u2013605","journal-title":"J Allergy Clin Immunol"},{"key":"8938_CR14","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","volume":"9","author":"JK Han","year":"2021","unstructured":"Han JK, Bachert C, Fokkens W, Desrosiers M, Wagenmann M, Lee SE et al (2021) Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 9:1141\u20131153","journal-title":"Lancet Respir Med"},{"key":"8938_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/2045-7022-3-3","volume":"3","author":"L Heinzerling","year":"2013","unstructured":"Heinzerling L, Mari A, Bergmann K-C, Bresciani M, Burbach G, Darsow U et al (2013) The skin prick test - European standards. Clin Transl Allergy 3:3. https:\/\/doi.org\/10.1186\/2045-7022-3-3","journal-title":"Clin Transl Allergy"},{"key":"8938_CR16","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1183\/09031936.05.00034805","volume":"26","author":"MR Miller","year":"2005","unstructured":"Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A et al (2005) Standardisation of spirometry. Eur Respir J 26:319\u2013338","journal-title":"Eur Respir J"},{"key":"8938_CR17","unstructured":"GINA Main Report 2021.Available from: https:\/\/ginasthma.org\/wp-content\/uploads\/2021\/05\/GINA-Main-Report-2021-V2-WMS.pdf. [cited 2021 Nov 21]"},{"key":"8938_CR18","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jaci.2012.07.047","volume":"131","author":"P Gevaert","year":"2013","unstructured":"Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W et al (2013) Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol 131:110-116.e1","journal-title":"J Allergy Clin Immunol"},{"key":"8938_CR19","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/all.12815","volume":"71","author":"I Abraham","year":"2016","unstructured":"Abraham I, Alhossan A, Lee CS, Kutbi H, MacDonald K (2016) \u2018Real-life\u2019 effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review. Allergy 71:593\u2013610","journal-title":"Allergy"},{"key":"8938_CR20","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.jaip.2017.02.002","volume":"5","author":"A Alhossan","year":"2017","unstructured":"Alhossan A, Lee CS, MacDonald K, Abraham I (2017) \u2018Real-life\u2019 effectiveness studies of omalizumab in adult patients with severe allergic asthma: meta-analysis. J Allergy Clin Immunol Pract 5:1362-1370.e2","journal-title":"J Allergy Clin Immunol Pract"},{"key":"8938_CR21","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1177\/19458924211030486","volume":"36","author":"C Damask","year":"2022","unstructured":"Damask C, Chen M, Holweg CTJ, Yoo B, Millette LA, Franzese C (2022) Defining the efficacy of omalizumab in nasal polyposis: a POLYP 1 and POLYP 2 subgroup analysis. Am J Rhinol Allergy 36:135\u2013141","journal-title":"Am J Rhinol Allergy"},{"key":"8938_CR22","unstructured":"Novartis. Xolair (omalizumab) label. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/103976s5238lbl.pdf#page=36. [cited 2021 Dec 21]"},{"key":"8938_CR23","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1111\/all.14809","volume":"76","author":"I Agache","year":"2021","unstructured":"Agache I, Song Y, Alonso-Coello P, Vogel Y, Rocha C, Sol\u00e0 I et al (2021) Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines. Allergy 76:2337\u20132353","journal-title":"Allergy"},{"key":"8938_CR24","first-page":"501","volume":"59","author":"S Tsabouri","year":"2021","unstructured":"Tsabouri S, Ntritsos G, Koskeridis F, Evangelou E, Olsson P, Kostikas K (2021) Omalizumab for the treatment of allergic rhinitis: a systematic review and meta-analysis. Rhinology 59:501\u2013510","journal-title":"Rhinology"},{"key":"8938_CR25","doi-asserted-by":"publisher","first-page":"42","DOI":"10.4193\/Rhin17.139","volume":"56","author":"T Bidder","year":"2018","unstructured":"Bidder T, Sahota J, Rennie C, Lund VJ, Robinson DS, Kariyawasam HH (2018) Omalizumab treats chronic rhinosinusitis with nasal polyps and asthma together-a real life study. Rhinology 56:42\u201345","journal-title":"Rhinology"},{"key":"8938_CR26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13601-020-00330-1","volume":"10","author":"E Heffler","year":"2020","unstructured":"Heffler E, Saccheri F, Bartezaghi M, Canonica GW (2020) Effectiveness of omalizumab in patients with severe allergic asthma with and without chronic rhinosinusitis with nasal polyps: a PROXIMA study post hoc analysis. Clin Transl Allergy 10:25. https:\/\/doi.org\/10.1186\/s13601-020-00330-1","journal-title":"Clin Transl Allergy"},{"key":"8938_CR27","doi-asserted-by":"publisher","first-page":"470","DOI":"10.18176\/jiaci.0602","volume":"30","author":"J Ruiz-Hornillos","year":"2020","unstructured":"Ruiz-Hornillos J, Rodr\u00edguez Jim\u00e9nez B, Feliu Vila A, Moreno Fern\u00e1ndez A, Hern\u00e1ndez Garc\u00eda MJ, Dom\u00ednguez-Ortega J et al (2020) Omalizumab as a therapeutic option for nasal polyposis in moderate-to-severe persistent allergic asthma: evidence from a prospective study in a real-world setting. J Investig Allergol Clin Immunol 30:470\u2013472","journal-title":"J Investig Allergol Clin Immunol"},{"key":"8938_CR28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.18176\/jiaci.0391","volume":"30","author":"A Tiotiu","year":"2020","unstructured":"Tiotiu A, Oster JP, Roux PR, Nguyen Thi PL, Peiffer G, Bonniaud P et al (2020) Effectiveness of omalizumab in severe allergic asthma and nasal polyposis: a real-life study. J Investig Allergol Clin Immunol 30:49\u201357","journal-title":"J Investig Allergol Clin Immunol"},{"key":"8938_CR29","unstructured":"GlaxoSmithKline LLC. Nucala (mepolizumab) label. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761122s006,125526s018lbl.pdf. [cited 2021 Dec 26]"},{"key":"8938_CR30","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","volume":"371","author":"HG Ortega","year":"2014","unstructured":"Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A et al (2014) Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371:1198\u20131207","journal-title":"N Engl J Med"},{"key":"8938_CR31","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1016\/j.jaci.2018.09.033","volume":"143","author":"S Khatri","year":"2019","unstructured":"Khatri S, Moore W, Gibson PG, Leigh R, Bourdin A, Maspero J et al (2019) Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol 143:1742-1751.e7","journal-title":"J Allergy Clin Immunol"},{"key":"8938_CR32","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.jaci.2020.02.002","volume":"145","author":"P Howarth","year":"2020","unstructured":"Howarth P, Chupp G, Nelsen LM, Bradford ES, Bratton DJ, Smith SG et al (2020) Severe eosinophilic asthma with nasal polyposis: a phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy. J Allergy Clin Immunol 145:1713\u20131715","journal-title":"J Allergy Clin Immunol"},{"key":"8938_CR33","unstructured":"AstraZeneca. Fasenra (benralizumab) label. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761070s005lbl.pdf. [cited 2021 Dec 28]"},{"key":"8938_CR34","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S2213-2600(20)30414-8","volume":"9","author":"TW Harrison","year":"2021","unstructured":"Harrison TW, Chanez P, Menzella F, Canonica GW, Louis R, Cosio BG et al (2021) Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respir Med 9:260\u2013274","journal-title":"Lancet Respir Med"},{"issue":"21","key":"8938_CR35","doi-asserted-by":"publisher","first-page":"01459","DOI":"10.1016\/j.jaci.2021.08.030","volume":"S0091\u20136749","author":"C Bachert","year":"2021","unstructured":"Bachert C, Han JK, Desrosiers MY, Gevaert P, Heffler E, Hopkins C et al (2021) Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial. J Allergy Clin Immunol S0091\u20136749(21):01459\u201301467. https:\/\/doi.org\/10.1016\/j.jaci.2021.08.030","journal-title":"J Allergy Clin Immunol"},{"key":"8938_CR36","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/all.14902","volume":"77","author":"GW Canonica","year":"2022","unstructured":"Canonica GW, Harrison TW, Chanez P, Menzella F, Louis R, Cosio BG et al (2022) Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis. Allergy 77:150\u2013161","journal-title":"Allergy"},{"key":"8938_CR37","doi-asserted-by":"publisher","first-page":"205873842095085","DOI":"10.1177\/2058738420950851","volume":"34","author":"N Lombardo","year":"2020","unstructured":"Lombardo N, Pelaia C, Ciriolo M, Della Corte M, Piazzetta G, Lobello N et al (2020) Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma. Int J Immunopathol Pharmacol 34:2058738420950851. https:\/\/doi.org\/10.1177\/2058738420950851","journal-title":"Int J Immunopathol Pharmacol"},{"key":"8938_CR38","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1164\/rccm.202009-3631CI","volume":"203","author":"SE Wenzel","year":"2021","unstructured":"Wenzel SE (2021) Severe adult asthmas: integrating clinical features, biology, and therapeutics to improve outcomes. Am J Respir Crit Care Med 203:809\u2013821","journal-title":"Am J Respir Crit Care Med"},{"key":"8938_CR39","doi-asserted-by":"publisher","first-page":"1902345","DOI":"10.1183\/13993003.02345-2019","volume":"55","author":"C Taill\u00e9","year":"2020","unstructured":"Taill\u00e9 C, Chanez P, Devouassoux G, Didier A, Pison C, Garcia G et al (2020) Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme. Eur Respir J 55:1902345. https:\/\/doi.org\/10.1183\/13993003.02345-2019","journal-title":"Eur Respir J"},{"key":"8938_CR40","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.chest.2020.08.2083","volume":"159","author":"JE Kavanagh","year":"2021","unstructured":"Kavanagh JE, Hearn AP, Dhariwal J, d\u2019Ancona G, Douiri A, Roxas C et al (2021) Real-world effectiveness of benralizumab in severe eosinophilic asthma. Chest 159:496\u2013506","journal-title":"Chest"},{"key":"8938_CR41","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1398-9995.2008.01846.x","volume":"64","author":"M Humbert","year":"2009","unstructured":"Humbert M, Boulet LP, Niven RM, Panahloo Z, Blogg M, Ayre G (2009) Omalizumab therapy: patients who achieve greatest benefit for their asthma experience greatest benefit for rhinitis. Allergy 64:81\u201384","journal-title":"Allergy"},{"key":"8938_CR42","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1111\/all.13373","volume":"73","author":"K Samitas","year":"2018","unstructured":"Samitas K, Carter A, Kariyawasam HH, Xanthou G (2018) Upper and lower airway remodelling mechanisms in asthma, allergic rhinitis and chronic rhinosinusitis: the one airway concept revisited. Allergy 73:993\u20131002","journal-title":"Allergy"},{"key":"8938_CR43","doi-asserted-by":"publisher","unstructured":"Tiotiu A, Novakova P, Baiardini I, Bikov A, Chong-Neto H, de-Sousa JC et al (2021) Manifesto on united airways diseases (UAD): an Interasma (global asthma association - GAA) document. J Asthma\u00a01\u201316.\u00a0https:\/\/doi.org\/10.1080\/02770903.2021.1879130","DOI":"10.1080\/02770903.2021.1879130"},{"key":"8938_CR44","doi-asserted-by":"publisher","first-page":"435","DOI":"10.14639\/0392-100X-N0716","volume":"40","author":"F Bandi","year":"2020","unstructured":"Bandi F, Gallo S, Preti A, Mozzanica F, Visca D, Marelli M et al (2020) Effects of biological therapies on chronic rhinosinusitis in severe asthmatic patients. Acta Otorhinolaryngol Ital 40:435\u2013443","journal-title":"Acta Otorhinolaryngol Ital"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-022-08938-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-022-08938-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-022-08938-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T19:46:07Z","timestamp":1679859967000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-022-08938-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,14]]},"references-count":44,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["8938"],"URL":"https:\/\/doi.org\/10.1007\/s12016-022-08938-w","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,14]]},"assertion":[{"value":"7 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Iulia Ioan, Rodrigo Romero-Fernandez, Thi-cam-tu Hoang and Diana Carolina Ochoa-Gutierrez have no conflicts of interest. Angelica Tiotiu reports speaker and consulting fees from ALK, AstraZeneca, GSK, Novartis and Sanofi outside the submitted work. Paula M\u00e9ndez-Brea Paula reports personal fees from ALK, Allergy Therapeutics, Chiesi, GSK and Stallergenes outside the submitted work. Jean Philippe Oster reports speaker and consulting fees from AstraZeneca, GSK, Novartis and Sanofi outside the submitted work. Pauline Roux reports speaker and consulting fees from AstraZeneca, Chiesi, GSK and Novartis outside the submitted work. Philippe Bonniaud reports speaker and consulting fees from AstraZeneca, Chiesi, GSK, Novartis and Sanofi outside the submitted work. Frederic de Blay reports speaker and consulting fees from ALK, AstraZeneca, Chiesi, GSK, Novartis and Sanofi outside the submitted work. Francisco-Javier Gonzalez-Barcala has received speaker fees, consulting fees or research grants from ALK, AstraZeneca, Bial, Boehringer-Ingelheim, Chiesi, Gebro Pharma, GSK, Laboratorios Esteve, Menarini, Mundipharma, Novartis, Rovi, Roxall, Sanofi, Stallergenes and Teva.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}